A Phase 2 interventional study of SAGE-547 and Placebo in Essential Tremor, sponsored by Sage Therapeutics. Completed at 2 sites in United States. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-06-29.
Sponsored by Sage Therapeutics (part of Supernus Pharmaceuticals, Inc.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 146 studies in Essential Tremor with a site in United States — 40 open to participants now, 46 under way, 1 of them phase 3. Essential Tremor · United States.
Among the 146 studies in Essential Tremor with a site in United States, this one is the 55th largest by enrollment of the 104 interventional ones that give a count, is one of 9 that started in 2014, is one of 21 in phase 2, and was the 49th registered.
272 studies on the registry are indexed under Essential Tremor; 75 are open to participants now.
Browse Essential Tremor studies →40 of the 146 studies in Essential Tremor with a site in United States are open now. Recruiting first, the newest first:
Encora, Inc. · Sites in United States
Ages 18+
AbbVie · Sites in United States, Canada
Ages 18–85
University of California, Los Angeles · Sites in United States
Ages 18–90
CND Life Sciences · Sites in United States
Ages 50–85
Boston University Charles River Campus · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 61 Essential Tremor studies recruiting now, 32 (52%) set no upper age limit and 5 (8%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.
This study: 35 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
146 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 27 · Phase 3 5 · Phase 4 5
First in 2000; this study’s year is marked. 9 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is close to the median of 25 across 189 interventional studies indexed under Essential Tremor.
Median enrollment 30 across the 104 interventional studies, 81 across the 41 observational. Of the 86 that completed or were terminated, 39 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 146 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sage Therapeutics, one of the names counted as Supernus Pharmaceuticals, Inc.. Under that name alone:
Sage Therapeutics is the lead sponsor of 6 studies on the registry; none are open to participants now.
Supernus Pharmaceuticals, Inc. has 4 studies filed under Essential Tremor — fewer than ten, so there is no comparison to draw.
13 of the studies in Essential Tremor with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03778060Mayo ClinicLong-Term Transcutaneous Stimulation and Essential Tremor: A PET Study | 2026-12 |
| NCT07599592University of California, Los AngelesOpen Label Study for the Use of Low Intensity Focused Ultrasound for Essential Tremor | 2026-12-31 |
| NCT07428447CND Life SciencesAnalysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease | 2027-02 |
| NCT04286308Massachusetts General HospitalCortical-Basal Ganglia Speech Networks | 2027-02 |
| NCT02553525Duke UniversityEffects of Stimulation Patterns of Deep Brain Stimulation | 2027-03 |
Add all 13 to your calendar (.ics) → With an account.
Among the 146 studies in Essential Tremor with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Stage 1 is a double-blind, proof-of-concept study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of SAGE-547 Injection in male and female participants with essential tremor in the upper limb.
Stage 2 is an open-label arm designed to evaluate the safety, tolerability, PK, and effectiveness of SAGE-547 Injection at a higher dose than in Stage 1. Participants who completed Stage 1 were invited to participate in Stage 2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a 12-hour intravenous (IV) infusion of SAGE 547, at ascending doses of 29, 58, and 86 micrograms per kilogram of body weight per hour (μg/kg/h), 4 hours each, on Day 1 of Stage 1 \[Treatment Period 1 (TP 1)\]. After a washout period of approximately 7 days, participants received a 12-hour IV infusion of SAGE-547 matching-placebo, on Day 10 of Stage 1 \[Treatment Period 2 (TP 2)\].
Drug: SAGE-547 · Drug: Placebo
Participants received a 12-hour IV infusion of SAGE-547 matching-placebo on Day 1 of Stage 1 (TP 1). After a washout period of approximately 7 days, participants received a 12-hour IV infusion of SAGE 547 at ascending doses of 29, 58, and 86 μg/kg/h, 4 hours each, on Day 10 of Stage 1 (TP 2).
Drug: SAGE-547 · Drug: Placebo
Participants who completed Stage 1 were invited to receive a 10-hour IV infusion of SAGE 547, at ascending doses of 90 μg/kg/h for 1 hour, 120 μg/kg/h for 1 hour, and 150 μg/kg/h for 8 hours on Day 1 of Stage 2.
Drug: SAGE-547
Stage 1: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
An adverse event (AE) is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A TEAE was defined as an AE with start date/time after the start of initial infusion in each stage. An SAE is defined as an AE or suspected adverse reaction, which in the view of either the Investigator or Sponsor, results in any of the following outcomes: death; is life-threatening; inpatient hospitalization or prolongation of existing hospitalization; a persistent or significant disability or incapacity; congenital anomaly or birth defect or other medically important condition.
Time frame: Stage 1: Up to 30 days after last infusion (up to Day 40)
Stage 2: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A TEAE was defined as an AE with start date/time after the start of initial infusion in each stage. An SAE is defined as an AE or suspected adverse reaction, which in the view of either the Investigator or Sponsor, results in any of the following outcomes: death; is life-threatening; inpatient hospitalization or prolongation of existing hospitalization; a persistent or significant disability or incapacity; congenital anomaly or birth defect or other medically important condition.
Time frame: Stage 2: Up to 30 days after last infusion (up to Day 31)
Stage 1: Percentage of Participants With a Response of 'Yes' to Any Columbia Suicide Severity Rating Scale (C-SSRS) Suicidal Ideation or Suicidal Behavior Item at Any Visit
The C-SSRS scale consisted of baseline evaluation that assessed lifetime experience of participants with suicidal ideation (SI) and suicidal behavior (SB) and postbaseline evaluation that focused on suicidality since last study visit. C-SSRS included "yes" or "no"' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, if present \[from 1 (minor physical damage) to 5 (death), with 5 being most severe\]. C-SSRS SI items involved (a) wish to be dead, (b) non-specific active suicidal thoughts, (c) active SI with any methods (not plan) without intent to act, (d) active SI with some intent to act, without specific plan and (e) active SI with specific plan and intent. C-SSRS SB items involved (a) actual attempt, (b) engaged in non-suicidal self-injurious behavior, (c) interrupted attempt, (d) aborted attempt, (e) preparatory acts or behavior, (f) suicidal behavior. Only categories with data are reported.
Time frame: Stage 1: Pre-infusion on Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2)
Stage 2: Percentage of Participants With a Response of 'Yes' to Any Columbia Suicide Severity Rating Scale (C-SSRS) Suicidal Ideation or Suicidal Behavior Item at Any Visit
The C-SSRS scale consisted of baseline evaluation that assessed lifetime experience of participants with SI and SB and postbaseline evaluation that focused on suicidality since last study visit. C-SSRS included "yes" or "no"' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, if present \[from 1 (minor physical damage) to 5 (death), with 5 being most severe\]. C-SSRS SI items involved (a) wish to be dead, (b) non-specific active suicidal thoughts, (c) active SI with any methods (not plan) without intent to act, (d) active SI with some intent to act, without specific plan and (e) active SI with specific plan and intent. C-SSRS SB items involved (a) actual attempt, (b) engaged in non-suicidal self-injurious behavior, (c) interrupted attempt, (d) aborted attempt, (e) preparatory acts or behavior, (f) suicidal behavior.
Time frame: Stage 2 Day 1: Pre-infusion and 10 hours and 7-day follow-up post-infusion
Stage 1: Change From Baseline (CFB) in Vital Signs Parameter - Supine Systolic Blood Pressure
Vital signs included supine systolic blood pressure, supine diastolic blood pressure, supine heart rate, standing systolic blood pressure, standing diastolic blood pressure, standing heart rate, temperature, and respiratory rate. CFB in supine systolic blood pressure is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 4, 8, 12 hours during infusion and 12-hour follow-up post-infusion
Stage 2: Change From Baseline in Vital Signs Parameter - Supine Systolic Blood Pressure
Vital signs included supine systolic blood pressure, supine diastolic blood pressure, supine heart rate, standing systolic blood pressure, standing diastolic blood pressure, standing heart rate, temperature, and respiratory rate. CFB in supine systolic blood pressure is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Stage 2 Day 1: Pre-infusion (Baseline) and 2, 4, 6, 8, 10, 12, 14 and 24 hours post-infusion
Stage 1: Change From Baseline in Vital Signs Parameter - Supine Diastolic Blood Pressure
Vital signs included supine systolic blood pressure, supine diastolic blood pressure, supine heart rate, standing systolic blood pressure, standing diastolic blood pressure, standing heart rate, temperature, and respiratory rate. CFB in supine diastolic blood pressure is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 4, 8, 12 hours during infusion and 12-hour follow-up post-infusion
Stage 2: Change From Baseline in Vital Signs Parameter - Supine Diastolic Blood Pressure
Vital signs included supine systolic blood pressure, supine diastolic blood pressure, supine heart rate, standing systolic blood pressure, standing diastolic blood pressure, standing heart rate, temperature, and respiratory rate. CFB in supine diastolic blood pressure is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Stage 2 Day 1: Pre-infusion (Baseline) and 2, 4, 6, 8, 10, 12, 14 and 24 hours post-infusion
Stage 1: Change From Baseline in Vital Signs Parameter - Supine Heart Rate
Vital signs included supine systolic blood pressure, supine diastolic blood pressure, supine heart rate, standing systolic blood pressure, standing diastolic blood pressure, standing heart rate, temperature, and respiratory rate. CFB in supine heart rate is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 4, 8, 12 hours during infusion and 12-hour follow-up post-infusion
Stage 2: Change From Baseline in Vital Signs Parameter - Supine Heart Rate
Vital signs included supine systolic blood pressure, supine diastolic blood pressure, supine heart rate, standing systolic blood pressure, standing diastolic blood pressure, standing heart rate, temperature, and respiratory rate. CFB in supine heart rate is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Stage 2 Day 1: Pre-infusion (Baseline) and 2, 4, 6, 8, 10, 12, 14 and 24 hours post-infusion
Stage 1: Change From Baseline in Vital Signs Parameter - Standing Systolic Blood Pressure
Vital signs included supine systolic blood pressure, supine diastolic blood pressure, supine heart rate, standing systolic blood pressure, standing diastolic blood pressure, standing heart rate, temperature, and respiratory rate. CFB in standing systolic blood pressure is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 4, 8, 12 hours during infusion and 12-hour follow-up post-infusion
Stage 2: Change From Baseline in Vital Signs Parameter - Standing Systolic Blood Pressure
Vital signs included supine systolic blood pressure, supine diastolic blood pressure, supine heart rate, standing systolic blood pressure, standing diastolic blood pressure, standing heart rate, temperature, and respiratory rate. CFB in standing systolic blood pressure is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Stage 2 Day 1: Pre-infusion (Baseline) and 2, 4, 6, 8, 10, 12, 14 and 24 hours post-infusion
Stage 1: Change From Baseline in Vital Signs Parameter - Standing Diastolic Blood Pressure
Vital signs included supine systolic blood pressure, supine diastolic blood pressure, supine heart rate, standing systolic blood pressure, standing diastolic blood pressure, standing heart rate, temperature, and respiratory rate. CFB in standing diastolic blood pressure is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 4, 8, 12 hours during infusion and 12-hour follow-up post-infusion
Stage 2: Change From Baseline in Vital Signs Parameter - Standing Diastolic Blood Pressure
Vital signs included supine systolic blood pressure, supine diastolic blood pressure, supine heart rate, standing systolic blood pressure, standing diastolic blood pressure, standing heart rate, temperature, and respiratory rate. CFB in standing diastolic blood pressure is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Stage 2 Day 1: Pre-infusion (Baseline) and 2, 4, 6, 8, 10, 12, 14 and 24 hours post-infusion
Stage 1: Change From Baseline in Vital Signs Parameter - Standing Heart Rate
Vital signs included supine systolic blood pressure, supine diastolic blood pressure, supine heart rate, standing systolic blood pressure, standing diastolic blood pressure, standing heart rate, temperature, and respiratory rate. CFB in standing heart rate is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 4, 8, 12 hours during infusion and 12-hour follow-up post-infusion
Stage 2: Change From Baseline in Vital Signs Parameter - Standing Heart Rate
Vital signs included supine systolic blood pressure, supine diastolic blood pressure, supine heart rate, standing systolic blood pressure, standing diastolic blood pressure, standing heart rate, temperature, and respiratory rate. CFB in standing heart rate is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Stage 2 Day 1: Pre-infusion (Baseline) and 2, 4, 6, 8, 10, 12, 14 and 24 hours post-infusion
Stage 1: Change From Baseline in Vital Signs Parameter - Temperature
Vital signs included supine systolic blood pressure, supine diastolic blood pressure, supine heart rate, standing systolic blood pressure, standing diastolic blood pressure, standing heart rate, temperature, and respiratory rate. CFB in temperature is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 4, 8, 12 hours during infusion and 12-hour follow-up post-infusion
Stage 2: Change From Baseline in Vital Signs Parameter - Temperature
Vital signs included supine systolic blood pressure, supine diastolic blood pressure, supine heart rate, standing systolic blood pressure, standing diastolic blood pressure, standing heart rate, temperature, and respiratory rate. CFB in temperature is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Stage 2 Day 1: Pre-infusion (Baseline) and 2, 4, 6, 8, 10, 12, 14 and 24 hours post-infusion
Stage 1: Change From Baseline in Vital Signs Parameter - Respiratory Rate
Vital signs included supine systolic blood pressure, supine diastolic blood pressure, supine heart rate, standing systolic blood pressure, standing diastolic blood pressure, standing heart rate, temperature, and respiratory rate. CFB in respiratory rate is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 4, 8, 12 hours during infusion and 12-hour follow-up post-infusion
Stage 2: Change From Baseline in Vital Signs Parameter - Respiratory Rate
Vital signs included supine systolic blood pressure, supine diastolic blood pressure, supine heart rate, standing systolic blood pressure, standing diastolic blood pressure, standing heart rate, temperature, and respiratory rate. CFB in respiratory rate is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Stage 2 Day 1: Pre-infusion (Baseline) and 2, 4, 6, 8, 10, 12, 14 and 24 hours post-infusion
Stage 1: Change From Baseline in Serum Chemistry Parameter - Alanine Aminotransferase Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in alanine aminotransferase levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 12-hour follow-up post-infusion
Stage 2: Absolute Values of Serum Chemistry Parameter - Alanine Aminotransferase Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for alanine aminotransferase levels are reported in this outcome measure.
Time frame: Stage 2: Any day in Screening period (Day -7 up to Day -1) and any day in 7-day follow up
Stage 1: Change From Baseline in Serum Chemistry Parameter - Aspartate Aminotransferase Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in aspartate aminotransferase levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 12-hour follow-up post-infusion
Stage 2: Absolute Values of Serum Chemistry Parameter - Aspartate Aminotransferase Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for aspartate aminotransferase levels are reported in this outcome measure.
Time frame: Stage 2: Any day in Screening period (Day -7 up to Day -1) and any day in 7-day follow up
Stage 1: Change From Baseline in Serum Chemistry Parameter - Gamma Glutamyl Transferase Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in gamma glutamyl transferase levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 12-hour follow-up post-infusion
Stage 2: Absolute Values of Serum Chemistry Parameter - Gamma Glutamyl Transferase Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for gamma glutamyl transferase levels are reported in this outcome measure.
Time frame: Stage 2: Any day in Screening period (Day -7 up to Day -1) and any day in 7-day follow up
Stage 1: Change From Baseline in Serum Chemistry Parameter - Sodium Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in sodium levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 12-hour follow-up post-infusion
Stage 2: Absolute Values of Serum Chemistry Parameter - Sodium Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for sodium levels are reported in this outcome measure.
Time frame: Stage 2: Any day in Screening period (Day -7 up to Day -1) and any day in 7-day follow up
Stage 1: Change From Baseline in Serum Chemistry Parameter - Potassium Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in potassium levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 12-hour follow-up post-infusion
Stage 2: Absolute Values of Serum Chemistry Parameter - Potassium Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for potassium levels are reported in this outcome measure.
Time frame: Stage 2: Any day in Screening period (Day -7 up to Day -1) and any day in 7-day follow up
Stage 1: Change From Baseline in Serum Chemistry Parameter - Calcium Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in calcium levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 12-hour follow-up post-infusion
Stage 2: Absolute Values of Serum Chemistry Parameter - Calcium Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for calcium levels are reported in this outcome measure.
Time frame: Stage 2: Any day in Screening period (Day -7 up to Day -1) and any day in 7-day follow up
Stage 1: Change From Baseline in Serum Chemistry Parameter - Chloride Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in chloride levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 12-hour follow-up post-infusion
Stage 2: Absolute Values of Serum Chemistry Parameter - Chloride Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for chloride levels are reported in this outcome measure.
Time frame: Stage 2: Any day in Screening period (Day -7 up to Day -1) and any day in 7-day follow up
Stage 1: Change From Baseline in Serum Chemistry Parameter - Bicarbonate Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in bicarbonate levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 12-hour follow-up post-infusion
Stage 2: Absolute Values of Serum Chemistry Parameter - Bicarbonate Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for bicarbonate levels are reported in this outcome measure.
Time frame: Stage 2: Any day in Screening period (Day -7 up to Day -1) and any day in 7-day follow up
Stage 1: Change From Baseline in Serum Chemistry Parameter - Protein Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in protein levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 12-hour follow-up post-infusion
Stage 2: Absolute Values of Serum Chemistry Parameter - Protein Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for protein levels are reported in this outcome measure.
Time frame: Stage 2: Any day in Screening period (Day -7 up to Day -1) and any day in 7-day follow up
Stage 1: Change From Baseline in Serum Chemistry Parameter - Glucose Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in glucose levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 12-hour follow-up post-infusion
Stage 2: Absolute Values of Serum Chemistry Parameter - Glucose Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for glucose levels are reported in this outcome measure.
Time frame: Stage 2: Any day in Screening period (Day -7 up to Day -1) and any day in 7-day follow up
Stage 1: Change From Baseline in Serum Chemistry Parameter - Lactate Dehydrogenase Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in lactate dehydrogenase levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 12-hour follow-up post-infusion
Stage 2: Absolute Values of Serum Chemistry Parameter - Lactate Dehydrogenase Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for lactate dehydrogenase levels are reported in this outcome measure.
Time frame: Stage 2: Any day in Screening period (Day -7 up to Day -1) and any day in 7-day follow up
Stage 1: Change From Baseline in Serum Chemistry Parameter - Cholesterol Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in cholesterol levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 12-hour follow-up post-infusion
Stage 2: Absolute Values of Serum Chemistry Parameter - Cholesterol Level
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for cholesterol levels are reported in this outcome measure.
Time frame: Stage 2: Any day in Screening period (Day -7 up to Day -1) and any day in 7-day follow up
Stage 1: Change From Baseline in Serum Chemistry Parameter - Triglyceride Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in triglyceride levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 12-hour follow-up post-infusion
Stage 2: Absolute Values of Serum Chemistry Parameter - Triglyceride Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for triglyceride levels are reported in this outcome measure.
Time frame: Stage 2: Any day in Screening period (Day -7 up to Day -1) and any day in 7-day follow up
Stage 1: Change From Baseline in Serum Chemistry Parameter - Albumin Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in albumin levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 12-hour follow-up post-infusion
Stage 2: Absolute Values of Serum Chemistry Parameter - Albumin Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for albumin levels are reported in this outcome measure.
Time frame: Stage 2: Any day in Screening period (Day -7 up to Day -1) and any day in 7-day follow up
Stage 1: Change From Baseline in Serum Chemistry Parameter - Bilirubin Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in bilirubin levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 12-hour follow-up post-infusion
Stage 2: Absolute Values of Serum Chemistry Parameter - Bilirubin Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for bilirubin levels are reported in this outcome measure.
Time frame: Stage 2: Any day in Screening period (Day -7 up to Day -1) and any day in 7-day follow up
Stage 1: Change From Baseline in Serum Chemistry Parameter - Creatinine Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in creatinine levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 12-hour follow-up post-infusion
Stage 2: Absolute Values of Serum Chemistry Parameter - Creatinine Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for creatinine levels are reported in this outcome measure.
Time frame: Stage 2: Any day in Screening period (Day -7 up to Day -1) and any day in 7-day follow up
Stage 1: Change From Baseline in Serum Chemistry Parameter - Blood Urea Nitrogen Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in blood urea nitrogen levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 12-hour follow-up post-infusion
Stage 2: Absolute Values of Serum Chemistry Parameter - Blood Urea Nitrogen Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for blood urea nitrogen levels are reported in this outcome measure.
Time frame: Stage 2: Any day in Screening period (Day -7 up to Day -1) and any day in 7-day follow up
Stage 1: Change From Baseline in Serum Chemistry Parameter - Alkaline Phosphatase Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in alkaline phosphatase levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 12-hour follow-up post-infusion
Stage 2: Absolute Values of Serum Chemistry Parameter - Alkaline Phosphatase Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for alkaline phosphatase levels are reported in this outcome measure.
Time frame: Stage 2: Any day in Screening period (Day -7 up to Day -1) and any day in 7-day follow up
Stage 1: Change From Baseline in Serum Chemistry Parameter - Creatine Kinase Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in creatinine kinase levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 12-hour follow-up post-infusion
Stage 2: Absolute Values of Serum Chemistry Parameter - Creatine Kinase Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for creatinine kinase levels are reported in this outcome measure.
Time frame: Stage 2: Any day in Screening period (Day -7 up to Day -1) and any day in 7-day follow up
Stage 1: Change From Baseline in Serum Chemistry Parameter - Phosphate Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in phosphate levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 12-hour follow-up post-infusion
Stage 2: Absolute Values of Serum Chemistry Parameter - Phosphate Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for phosphate levels are reported in this outcome measure.
Time frame: Stage 2: Any day in Screening period (Day -7 up to Day -1) and any day in 7-day follow up
Stage 1: Change From Baseline in Serum Chemistry Parameter - Urate Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in urate levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 12-hour follow-up post-infusion
Stage 2: Absolute Values of Serum Chemistry Parameter - Urate Levels
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for urate levels are reported in this outcome measure.
Time frame: Stage 2: Any day in Screening period (Day -7 up to Day -1) and any day in 7-day follow up
Stage 1: Change From Baseline in Hematology Parameter - Hemoglobin Levels
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. CFB in hemoglobin levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 12-hour follow-up post-infusion
Stage 2: Absolute Values of Hematology Parameter - Hemoglobin Levels
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. Absolute values for hemoglobin levels are reported in this outcome measure.
Time frame: Stage 2: Any day in Screening period (Day -7 up to Day -1) and any day in 7-day follow up
Stage 1: Change From Baseline in Hematology Parameter - Hematocrit Levels
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. CFB in hematocrit levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 12-hour follow-up post-infusion
Stage 2: Absolute Values of Hematology Parameter - Hematocrit Levels
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. Absolute values for hematocrit levels are reported in this outcome measure.
Time frame: Stage 2: Any day in Screening period (Day -7 up to Day -1) and any day in 7-day follow up
Stage 1: Change From Baseline in Hematology Parameter - Platelet Levels
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. CFB in platelet levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 12-hour follow-up post-infusion
Stage 2: Absolute Values of Hematology Parameter - Platelet Levels
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. Absolute values for platelet levels are reported in this outcome measure.
Time frame: Stage 2: Any day in Screening period (Day -7 up to Day -1) and any day in 7-day follow up
Stage 1: Change From Baseline in Hematology Parameter - Erythrocyte Levels
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. CFB in erythrocyte levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 12-hour follow-up post-infusion
Stage 2: Absolute Values of Hematology Parameter - Erythrocyte Levels
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. Absolute values for erythrocyte levels are reported in this outcome measure.
Time frame: Stage 2: Any day in Screening period (Day -7 up to Day -1) and any day in 7-day follow up
Stage 1: Change From Baseline in Hematology Parameter - Neutrophil Levels
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. CFB in neutrophil levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 12-hour follow-up post-infusion
Stage 2: Absolute Values of Hematology Parameter - Neutrophil Levels
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. Absolute values for neutrophil levels are reported in this outcome measure.
Time frame: Stage 2: Any day in Screening period (Day -7 up to Day -1) and any day in 7-day follow up
Stage 1: Change From Baseline in Hematology Parameter - Basophil Levels
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. CFB in basophil levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 12-hour follow-up post-infusion
Stage 2: Absolute Values of Hematology Parameter - Basophil Levels
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. Absolute values for basophil levels are reported in this outcome measure.
Time frame: Stage 2: Any day in Screening period (Day -7 up to Day -1) and any day in 7-day follow up
Stage 1: Change From Baseline in Hematology Parameter - Eosinophil Levels
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. CFB in eosinophil levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 12-hour follow-up post-infusion
Stage 2: Absolute Values of Hematology Parameter - Eosinophil Levels
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. Absolute values for eosinophil levels are reported in this outcome measure.
Time frame: Stage 2: Any day in Screening period (Day -7 up to Day -1) and any day in 7-day follow up
Stage 1: Change From Baseline in Hematology Parameter - Monocyte Levels
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. CFB in monocyte levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 12-hour follow-up post-infusion
Stage 2: Absolute Values of Hematology Parameter - Monocyte Levels
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. Absolute values for monocyte levels are reported in this outcome measure.
Time frame: Stage 2: Any day in Screening period (Day -7 up to Day -1) and any day in 7-day follow up
Stage 1: Change From Baseline in Hematology Parameter - Lymphocyte Levels
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. CFB in lymphocyte levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 12-hour follow-up post-infusion
Stage 2: Absolute Values of Hematology Parameter - Lymphocyte Levels
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. Absolute values for lymphocyte levels are reported in this outcome measure.
Time frame: Stage 2: Any day in Screening period (Day -7 up to Day -1) and any day in 7-day follow up
Stage 1: Change From Baseline in Hematology Parameter - Leukocyte Levels
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. CFB in leukocyte levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 12-hour follow-up post-infusion
Stage 2: Absolute Values of Hematology Parameter - Leukocyte Levels
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. Absolute values for leukocyte levels are reported in this outcome measure.
Time frame: Stage 2: Any day in Screening period (Day -7 up to Day -1) and any day in 7-day follow up
Stage 1: Change From Baseline in Hematology Parameter - Erythrocytes Mean Corpuscular Volume Levels
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. CFB in erythrocytes mean corpuscular volume levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 12-hour follow-up post-infusion
Stage 2: Absolute Values of Hematology Parameter - Erythrocytes Mean Corpuscular Volume Levels
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. Absolute values for erythrocytes mean corpuscular volume levels are reported in this outcome measure.
Time frame: Stage 2: Any day in Screening period (Day -7 up to Day -1) and any day in 7-day follow up
Stage 1: Change From Baseline in Hematology Parameter - Mean Cell Hemoglobin Levels
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. CFB in mean cell hemoglobin levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 12-hour follow-up post-infusion
Stage 2: Absolute Values of Hematology Parameter - Mean Cell Hemoglobin
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. Absolute values for mean cell hemoglobin levels are reported in this outcome measure.
Time frame: Stage 2: Any day in Screening period (Day -7 up to Day -1) and any day in 7-day follow up
Stage 1: Change From Baseline in Electrocardiogram (ECG) Parameter - QT Interval
ECG parameters included QT interval, PR interval, QRS duration, QTcB interval, QTcF interval, and heart rate. CFB in QT interval is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 4, 8,12 hours during infusion
Stage 2: Change From Baseline in ECG Parameter - QT Interval
ECG parameters included QT interval, PR interval, QRS duration, QTcB interval, QTcF interval, and heart rate. CFB in QT interval is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Stage 2 Day 1: Pre-infusion (Baseline) and 10 hours post-infusion
Stage 1: Change From Baseline in ECG Parameter - PR Interval
ECG parameters included QT interval, PR interval, QRS duration, QTcB interval, QTcF interval, and heart rate. CFB in PR interval is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 4, 8,12 hours during infusion
Stage 2: Change From Baseline in ECG Parameter - PR Interval
ECG parameters included QT interval, PR interval, QRS duration, QTcB interval, QTcF interval, and heart rate. CFB in PR interval is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Stage 2 Day 1: Pre-infusion (Baseline) and 10 hours post-infusion
Stage 1: Change From Baseline in ECG Parameter - QRS Duration
ECG parameters included QT interval, PR interval, QRS duration, QTcB interval, QTcF interval, and heart rate. CFB in QRS duration is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 4, 8, 12 hours during infusion
Stage 2: Change From Baseline in ECG Parameter - QRS Duration
ECG parameters included QT interval, PR interval, QRS duration, QTcB interval, QTcF interval, and heart rate. CFB in QRS duration is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Stage 2 Day 1: Pre-infusion (Baseline) and 10 hours post-infusion
Stage 1: Change From Baseline in ECG Parameter - QTcB Interval
ECG parameters included QT interval, PR interval, QRS duration, QTcB interval, QTcF interval, and heart rate. CFB in QTcB interval is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 4, 8, 12 hours during infusion
Stage 2: Change From Baseline in ECG Parameter - QTcB Interval
ECG parameters included QT interval, PR interval, QRS duration, QTcB interval, QTcF interval, and heart rate. CFB in QTcB interval is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Stage 2 Day 1: Pre-infusion (Baseline) and 10 hours post-infusion
Stage 1: Change From Baseline in ECG Parameter - QTcF Interval
ECG parameters included QT interval, PR interval, QRS duration, QTcB interval, QTcF interval, and heart rate. CFB in QTcF interval is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 4, 8, 12 hours during infusion
Stage 2: Change From Baseline in ECG Parameter - QTcF Interval
ECG parameters included QT interval, PR interval, QRS duration, QTcB interval, QTcF interval, and heart rate. CFB in QTcF interval is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Stage 2 Day 1: Pre-infusion (Baseline) and 10 hours post-infusion
Stage 1: Change From Baseline in ECG Parameter - Heart Rate
ECG parameters included QT interval, PR interval, QRS duration, QTcB interval, QTcF interval, and heart rate. CFB in heart rate is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Day 1 of Stage 1 (Treatment Period 1) or on Day 10 of Stage 1 (Treatment Period 2): Pre-infusion (Baseline) and 4, 8, 12 hours during infusion
Stage 2: Change From Baseline in ECG Parameter - Heart Rate
ECG parameters included QT interval, PR interval, QRS duration, QTcB interval, QTcF interval, and heart rate. CFB in heart rate is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Stage 2 Day 1: Pre-infusion (Baseline) and 10 hours post-infusion
Stage 1: Change From Baseline in Accelerometer Total Score Response
Accelerometer total score response was defined as ≥30% decrease from baseline to each time point in accelerometer total score. Accelerometer total score is sum of forward outstretched postural tremor, lateral wing-beating postural tremor, and kinetic tremor scores across both sides of the body (i.e., right and left). Accelerometer was used for transducer measurement of tremor amplitude. Participants wore wireless ring motion sensor. It measured linear acceleration and angular velocity (i.e., kinesia score). Information from motion sensor data was correlated to symptoms of tremor. Kinesia (accelerometer) scores ranged from 0 to 4 in 0.5 step increments. The total score ranges from 0 to 24, higher scores indicating more severe tremors. Negative change from baseline indicated decrease in tremor. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Stage 1 Days 1 and 10: Pre-infusion (Baseline) and 2, 4, 6, 8, 10 and 12 hours and 12-hour follow-up post-infusion
Stage 2: Change From Baseline in Accelerometer Total Score Response
Accelerometer total score response was defined as ≥30% decrease from baseline to each time point in accelerometer total score. Accelerometer total score is sum of forward outstretched postural tremor, lateral wing beating postural tremor, and kinetic tremor scores across both sides of the body (i.e., right and left). Accelerometer was used for transducer measurement of tremor amplitude. Participants wore wireless ring motion sensor. It measured linear acceleration and angular velocity (i.e., kinesia score). Information from motion sensor data was correlated to symptoms of tremor. Kinesia (accelerometer) scores ranged from 0 to 4 in 0.5 step increments. The total score ranges from 0 to 24, higher scores indicating more severe tremors. Negative change from baseline indicated decrease in tremor. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Stage 2 Day 1: Baseline and 2, 3, 4, 6, 8, 10, 12, 14 and 24 hours
Stage 1: Change From Baseline in The Essential Tremor Rating Scale (TETRAS) Using Performance Subscale (PS) Part 4 Upper-Limb Total Scores
The TETRAS PS total score was calculated as the sum of items 4 (upper-limb), 6 (Archimedes spiral), 7 (handwriting), and 8 (dot approximation). TETRAS PS upper-limb total score was calculated as the sum of the 6 separate upper-limb maneuvers assessed by the clinician: forward-outstretched postural tremor \[right\], forward outstretched postural tremor \[left\], lateral wing-beating postural tremor \[right\], lateral wing-beating postural tremor \[left\], kinetic tremor \[right\], kinetic tremor \[left\], each on a 0 (no tremor) to 4 (maximum tremor) severity scale in 0.5-point increments. TETRAS Part 4 score for both upper limbs ranged from 0 to 24, higher scores indicated more severe tremor. A negative change from baseline indicated less tremor. Baseline is defined as the pre-infusion value in each period/stage.
Time frame: Stage 1 Days 1 and 10: Pre-infusion (Baseline) and 2, 4, 6, 8, 10 and 12 hours and 12-hour follow-up post-infusion
Stage 2: Change From Baseline in TETRAS Using PS Part 4 Upper-Limb Total Scores
The TETRAS PS total score was calculated as the sum of items 4 (upper-limb), 6 (Archimedes spiral), 7 (handwriting), and 8 (dot approximation). TETRAS PS upper-limb total score was calculated as the sum of the 6 separate upper-limb maneuvers assessed by the clinician: forward-outstretched postural tremor \[right\], forward outstretched postural tremor \[left\], lateral wing-beating postural tremor \[right\], lateral wing-beating postural tremor \[left\], kinetic tremor \[right\], kinetic tremor \[left\], each on a 0 (no tremor) to 4 (maximum tremor) severity scale in 0.5-point increments. TETRAS Part 4 score for both upper limbs ranged from 0 to 24, higher scores indicated more severe tremor. A negative change from baseline indicated less tremor.
Time frame: Stage 2 Day 1: Baseline and at 2, 3, 4, 6, 8, 10, 12, 14 and 24 hours
Stage 1: Change From Baseline in Stanford Sleepiness Scale (SSS) Score
SSS is a participant-rated scale designed to quickly assess how alert a participant was feeling. Degrees of sleepiness and alertness were rated on a scale of 1 to 7, where the lowest score of '1' indicated the participant was 'feeling active, vital, alert, or wide awake' and the highest score of '7' indicated the participant was 'no longer fighting sleep, sleep onset soon; having dream-like thoughts'. Baseline is defined as the pre-infusion value in each period. A negative change from baseline indicated less sleepiness.
Time frame: Stage 1 Day 1 and 10: Pre-infusion (Baseline) and 2, 4, 6, 8, 10 and 12 hours and 12-hour follow-up post-infusion
Stage 2: Change From Baseline in Stanford Sleepiness Scale (SSS) Score
SSS is a participant-rated scale designed to quickly assess how alert a participant was feeling. Degrees of sleepiness and alertness were rated on a scale of 1 to 7, where the lowest score of '1' indicated the participant was 'feeling active, vital, alert, or wide awake' and the highest score of '7' indicated the participant was 'no longer fighting sleep, sleep onset soon; having dream-like thoughts'. Baseline is defined as the pre-infusion value in each period. A negative change from baseline indicated less sleepiness.
Time frame: Stage 2 Day 1: Baseline and at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 and 24 hours
Stage 1: Maximum Peak Plasma Concentration (Cmax) of SAGE-547
Time frame: Stage 1: Pre-infusion and after the start of infusion at 30 and 40 minutes and at 1, 1.5, 2, 4, 6, 8, 10, 12, 12.5, 12.75, 13, 13.5, 14, 16 and 24 hours
Stage 2: Maximum Peak Plasma Concentration (Cmax) of SAGE-547
Time frame: Stage 2: Pre-infusion and at 30, 60, 90 and 120 minutes and at 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 10.5, 10.75, 11, 11.5, 12, 14, 16 and 24 hours after start of the infusion
Stage 1: Time to Maximum Peak Plasma Concentration (Cmax) of SAGE-547
Time frame: Stage 1: Pre-infusion and after the start of infusion at 30 and 40 minutes and at 1, 1.5, 2, 4, 6, 8, 10, 12, 12.5, 12.75, 13, 13.5, 14, 16 and 24 hours
Stage 2: Time to Maximum Peak Plasma Concentration (Cmax) of SAGE-547
Time frame: Stage 2: Pre-infusion and at 30, 60, 90 and 120 minutes and at 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 10.5, 10.75, 11, 11.5, 12, 14, 16 and 24 hours after start of the infusion
Stage 1: Area Under the Plasma Concentration Time Curve up to the Time of the Last Quantifiable Sample (AUClast) of SAGE-547
Time frame: Stage 1: Pre-infusion and after the start of infusion at 30 and 40 minutes and at 1, 1.5, 2, 4, 6, 8, 10, 12, 12.5, 12.75, 13, 13.5, 14, 16 and 24 hours
Stage 2: Area Under the Plasma Concentration Time Curve up to the Time of the Last Quantifiable Sample (AUClast) of SAGE-547
Time frame: Day 1: Pre-infusion and at 30, 60, 90 and 120 minutes and at 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 10.5, 10.75, 11, 11.5, 12, 14, 16 and 24 hours after start of the infusion
Stage 1: Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of SAGE-547
Time frame: Stage 1: Pre-infusion and after the start of infusion at 30 and 40 minutes and at 1, 1.5, 2, 4, 6, 8, 10, 12, 12.5, 12.75, 13, 13.5, 14, 16 and 24 hours
Stage 2: Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of SAGE-547
Time frame: Stage 2: Pre-infusion and at 30, 60, 90 and 120 minutes and at 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 10.5, 10.75, 11, 11.5, 12, 14, 16 and 24 hours after start of the infusion
Stage 1: Clearance (CL) of SAGE-547
Clearance is defined as the volume of plasma from which a substance is completely removed per unit time.
Time frame: Stage 1: Pre-infusion and after the start of infusion at 30 and 40 minutes and at 1, 1.5, 2, 4, 6, 8, 10, 12, 12.5, 12.75, 13, 13.5, 14, 16 and 24 hours
Stage 2: Clearance (CL) of SAGE-547
Clearance is defined as the volume of plasma from which a substance is completely removed per unit time.
Time frame: Stage 2: Pre-infusion and at 30, 60, 90 and 120 minutes and at 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 10.5, 10.75, 11, 11.5, 12, 14, 16 and 24 hours after start of the infusion
Stage 1: Terminal Half-Life (t½) of SAGE-547
Terminal half-life is defined as the time required to divide the plasma concentration by two after reaching pseudo-equilibrium.
Time frame: Stage 1: Pre-infusion and after the start of infusion at 30 and 40 minutes and at 1, 1.5, 2, 4, 6, 8, 10, 12, 12.5, 12.75, 13, 13.5, 14, 16 and 24 hours
Stage 2: Terminal Half-Life (t½) of SAGE-547
Terminal half-life is defined as the time required to divide the plasma concentration by two after reaching pseudo-equilibrium.
Time frame: Stage 2: Pre-infusion and at 30, 60, 90 and 120 minutes and at 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 10.5, 10.75, 11, 11.5, 12, 14, 16 and 24 hours after start of the infusion
Participants were enrolled at 2 investigative sites in the United States from 23 September 2014 to 14 August 2015.
| Milestone | Stage 1 (Double-blind): SAGE 547, Then Placebo | Stage 1 (Double-blind): Placebo, Then SAGE-547 | Stage 2 (Open Label): SAGE-547 |
|---|---|---|---|
| Started | 13 | 12 | 0 |
| Completed | 13 | 12 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | Stage 1 (Double-blind): SAGE 547, Then Placebo | Stage 1 (Double-blind): Placebo, Then SAGE-547 | Stage 2 (Open Label): SAGE-547 |
|---|---|---|---|
| Started | 13 | 12 | 0 |
| Completed | 13 | 12 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | Stage 1 (Double-blind): SAGE 547, Then Placebo | Stage 1 (Double-blind): Placebo, Then SAGE-547 | Stage 2 (Open Label): SAGE-547 |
|---|---|---|---|
| Started | 13 | 12 | 0 |
| Completed | 13 | 12 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | Stage 1 (Double-blind): SAGE 547, Then Placebo | Stage 1 (Double-blind): Placebo, Then SAGE-547 | Stage 2 (Open Label): SAGE-547 |
|---|---|---|---|
| Started | 0 | 0 | 17 |
| Completed | 0 | 0 | 16 |
| Not completed | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 1 |
An adverse event (AE) is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A TEAE was defined as an AE with start date/time after the start of initial infusion in each stage. An SAE is defined as an AE or suspected adverse reaction, which in the view of either the Investigator or Sponsor, results in any of the following outcomes: death; is life-threatening; inpatient hospitalization or prolongation of existing hospitalization; a persistent or significant disability or incapacity; congenital anomaly or birth defect or other medically important condition.
| percentage of participants | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| TEAEs | 12.0 | 20.0 |
| SAEs | 0 | 0 |
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A TEAE was defined as an AE with start date/time after the start of initial infusion in each stage. An SAE is defined as an AE or suspected adverse reaction, which in the view of either the Investigator or Sponsor, results in any of the following outcomes: death; is life-threatening; inpatient hospitalization or prolongation of existing hospitalization; a persistent or significant disability or incapacity; congenital anomaly or birth defect or other medically important condition.
| percentage of participants | Stage 2: SAGE-547 |
|---|---|
| TEAEs | 47.1 |
| SAEs | 0 |
The C-SSRS scale consisted of baseline evaluation that assessed lifetime experience of participants with suicidal ideation (SI) and suicidal behavior (SB) and postbaseline evaluation that focused on suicidality since last study visit. C-SSRS included "yes" or "no"' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, if present \[from 1 (minor physical damage) to 5 (death), with 5 being most severe\]. C-SSRS SI items involved (a) wish to be dead, (b) non-specific active suicidal thoughts, (c) active SI with any methods (not plan) without intent to act, (d) active SI with some intent to act, without specific plan and (e) active SI with specific plan and intent. C-SSRS SB items involved (a) actual attempt, (b) engaged in non-suicidal self-injurious behavior, (c) interrupted attempt, (d) aborted attempt, (e) preparatory acts or behavior, (f) suicidal behavior. Only categories with data are reported.
| percentage of participants | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Suicidal Ideation: Wish to be Dead: Pre-infusion | 0 | 4.0 |
| Suicidal Ideation: Non-specific Active Suicidal Thoughts: Pre-infusion | 4.0 | 0 |
| Suicidal Behavior: Actual Attempt: Pre-infusion | 4.0 | 4.0 |
The C-SSRS scale consisted of baseline evaluation that assessed lifetime experience of participants with SI and SB and postbaseline evaluation that focused on suicidality since last study visit. C-SSRS included "yes" or "no"' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, if present \[from 1 (minor physical damage) to 5 (death), with 5 being most severe\]. C-SSRS SI items involved (a) wish to be dead, (b) non-specific active suicidal thoughts, (c) active SI with any methods (not plan) without intent to act, (d) active SI with some intent to act, without specific plan and (e) active SI with specific plan and intent. C-SSRS SB items involved (a) actual attempt, (b) engaged in non-suicidal self-injurious behavior, (c) interrupted attempt, (d) aborted attempt, (e) preparatory acts or behavior, (f) suicidal behavior.
| percentage of participants | Stage 2: SAGE-547 |
|---|---|
| Stage 2: Percentage of Participants With a Response of 'Yes' to Any Columbia Suicide Severity Rating Scale (C-SSRS) Suicidal Ideation or Suicidal Behavior Item at Any Visit | 0 |
Vital signs included supine systolic blood pressure, supine diastolic blood pressure, supine heart rate, standing systolic blood pressure, standing diastolic blood pressure, standing heart rate, temperature, and respiratory rate. CFB in supine systolic blood pressure is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| millimeters of mercury (mmHg) | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 121.6 ± 11.58 | 120.2 ± 15.47 |
| CFB at 4 Hours | -2.5 ± 10.84 | 4.0 ± 11.71 |
| CFB at 8 Hours | -3.9 ± 11.64 | 3.5 ± 10.24 |
| CFB at 12 Hours | -1.6 ± 10.44 | 7.6 ± 10.14 |
| CFB at 12-hour Follow-up | 5.6 ± 8.68 | 1.4 ± 11.85 |
Vital signs included supine systolic blood pressure, supine diastolic blood pressure, supine heart rate, standing systolic blood pressure, standing diastolic blood pressure, standing heart rate, temperature, and respiratory rate. CFB in supine systolic blood pressure is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| mmHg | Stage 2: SAGE-547 |
|---|---|
| Pre-infusion | 125.3 ± 13.22 |
| CFB at 2 Hours | -12.1 ± 14.95 |
| CFB at 4 Hours | -7.6 ± 17.12 |
| CFB at 6 Hours | -7.9 ± 14.01 |
| CFB at 8 Hours | -6.8 ± 17.44 |
| CFB at 10 Hours | -2.9 ± 13.48 |
| CFB at 12 Hours | 4.0 ± 13.22 |
| CFB at 14 Hours | 3.1 ± 18.44 |
| CFB at 24 Hours | 4.3 ± 11.12 |
Vital signs included supine systolic blood pressure, supine diastolic blood pressure, supine heart rate, standing systolic blood pressure, standing diastolic blood pressure, standing heart rate, temperature, and respiratory rate. CFB in supine diastolic blood pressure is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| mmHg | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 74.3 ± 8.90 | 75.0 ± 11.24 |
| CFB at 4 Hours | -2.3 ± 9.85 | -0.6 ± 6.10 |
| CFB at 8 Hours | -2.0 ± 6.79 | -0.7 ± 8.27 |
| CFB at 12 Hours | 0.4 ± 8.33 | 1.2 ± 9.69 |
| CFB at 12-hour Follow-up | 2.0 ± 8.17 | 0.8 ± 9.68 |
Vital signs included supine systolic blood pressure, supine diastolic blood pressure, supine heart rate, standing systolic blood pressure, standing diastolic blood pressure, standing heart rate, temperature, and respiratory rate. CFB in supine diastolic blood pressure is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| mmHg | Stage 2: SAGE-547 |
|---|---|
| Pre-infusion | 75.5 ± 7.63 |
| CFB at 2 Hours | -7.9 ± 8.59 |
| CFB at 4 Hours | -6.4 ± 10.20 |
| CFB at 6 Hours | -4.6 ± 9.70 |
| CFB at 8 Hours | -8.8 ± 10.17 |
| CFB at 10 Hours | -2.4 ± 9.52 |
| CFB at 12 Hours | 0.3 ± 8.80 |
| CFB at 14 Hours | -2.2 ± 9.03 |
| CFB at 24 Hours | -0.3 ± 8.99 |
Vital signs included supine systolic blood pressure, supine diastolic blood pressure, supine heart rate, standing systolic blood pressure, standing diastolic blood pressure, standing heart rate, temperature, and respiratory rate. CFB in supine heart rate is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| beats per minute (bpm) | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 66.0 ± 9.70 | 69.0 ± 12.99 |
| CFB at 4 Hours | -1.4 ± 7.52 | -2.1 ± 10.39 |
| CFB at 8 Hours | 2.0 ± 6.37 | 1.3 ± 14.85 |
| CFB at 12 Hours | 5.0 ± 8.67 | 2.1 ± 11.23 |
| CFB at 12-hour Follow-up | 2.9 ± 9.17 | -2.3 ± 8.96 |
Vital signs included supine systolic blood pressure, supine diastolic blood pressure, supine heart rate, standing systolic blood pressure, standing diastolic blood pressure, standing heart rate, temperature, and respiratory rate. CFB in supine heart rate is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| bpm | Stage 2: SAGE-547 |
|---|---|
| Pre-infusion | 69.5 ± 10.96 |
| CFB at 2 Hours | 0.7 ± 10.18 |
| CFB at 4 Hours | -3.3 ± 7.22 |
| CFB at 6 Hours | -3.3 ± 10.30 |
| CFB at 8 Hours | -1.5 ± 9.00 |
| CFB at 10 Hours | -1.5 ± 9.10 |
| CFB at 12 Hours | -2.1 ± 8.55 |
| CFB at 14 Hours | 3.9 ± 10.29 |
| CFB at 24 Hours | 2.6 ± 8.70 |
Vital signs included supine systolic blood pressure, supine diastolic blood pressure, supine heart rate, standing systolic blood pressure, standing diastolic blood pressure, standing heart rate, temperature, and respiratory rate. CFB in standing systolic blood pressure is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| mmHg | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 118.0 ± 17.27 | 119.1 ± 15.00 |
| CFB at 4 Hours | -2.2 ± 10.70 | 1.7 ± 12.48 |
| CFB at 8 Hours | -2.7 ± 13.23 | 1.0 ± 12.87 |
| CFB at 12 Hours | 2.0 ± 12.65 | 7.8 ± 11.48 |
| CFB at 12-hour Follow-up | 5.0 ± 15.82 | 1.7 ± 10.76 |
Vital signs included supine systolic blood pressure, supine diastolic blood pressure, supine heart rate, standing systolic blood pressure, standing diastolic blood pressure, standing heart rate, temperature, and respiratory rate. CFB in standing systolic blood pressure is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| mmHg | Stage 2: SAGE-547 |
|---|---|
| Pre-infusion | 120.1 ± 13.05 |
| CFB at 2 Hours | -5.5 ± 15.98 |
| CFB at 4 Hours | -5.9 ± 13.87 |
| CFB at 6 Hours | -1.0 ± 16.84 |
| CFB at 8 Hours | -2.9 ± 14.22 |
| CFB at 10 Hours | -0.9 ± 16.49 |
| CFB at 12 Hours | 10.2 ± 17.28 |
| CFB at 14 Hours | 11.1 ± 18.98 |
| CFB at 24 Hours | 2.9 ± 9.30 |
Vital signs included supine systolic blood pressure, supine diastolic blood pressure, supine heart rate, standing systolic blood pressure, standing diastolic blood pressure, standing heart rate, temperature, and respiratory rate. CFB in standing diastolic blood pressure is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| mmHg | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 76.2 ± 10.20 | 78.9 ± 11.84 |
| CFB at 4 Hours | -1.2 ± 8.86 | -3.1 ± 6.81 |
| CFB at 8 Hours | -2.1 ± 9.03 | -2.6 ± 7.34 |
| CFB at 12 Hours | 1.0 ± 9.53 | 0.6 ± 9.31 |
| CFB at 12-hour Follow-up | 2.7 ± 9.85 | 0.9 ± 6.65 |
Vital signs included supine systolic blood pressure, supine diastolic blood pressure, supine heart rate, standing systolic blood pressure, standing diastolic blood pressure, standing heart rate, temperature, and respiratory rate. CFB in standing diastolic blood pressure is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| mmHg | Stage 2: SAGE-547 |
|---|---|
| Pre-infusion | 78.9 ± 8.81 |
| CFB at 2 Hours | -5.6 ± 7.17 |
| CFB at 4 Hours | -4.5 ± 8.43 |
| CFB at 6 Hours | -4.1 ± 6.66 |
| CFB at 8 Hours | -4.7 ± 6.03 |
| CFB at 10 Hours | -4.3 ± 9.21 |
| CFB at 12 Hours | -1.3 ± 8.30 |
| CFB at 14 Hours | -0.6 ± 8.73 |
| CFB at 24 Hours | -1.5 ± 6.52 |
Vital signs included supine systolic blood pressure, supine diastolic blood pressure, supine heart rate, standing systolic blood pressure, standing diastolic blood pressure, standing heart rate, temperature, and respiratory rate. CFB in standing heart rate is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| bpm | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 72.0 ± 9.66 | 75.6 ± 13.70 |
| CFB at 4 Hours | 0.0 ± 7.13 | -1.0 ± 9.17 |
| CFB at 8 Hours | 3.0 ± 7.55 | -0.0 ± 10.22 |
| CFB at 12 Hours | 5.4 ± 11.84 | 3.4 ± 8.23 |
| CFB at 12-hour Follow-up | 3.8 ± 8.15 | -1.5 ± 9.38 |
Vital signs included supine systolic blood pressure, supine diastolic blood pressure, supine heart rate, standing systolic blood pressure, standing diastolic blood pressure, standing heart rate, temperature, and respiratory rate. CFB in standing heart rate is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| bpm | Stage 2: SAGE-547 |
|---|---|
| Pre-infusion | 74.6 ± 10.12 |
| CFB at 2 Hours | 1.2 ± 9.25 |
| CFB at 4 Hours | 0.7 ± 7.69 |
| CFB at 6 Hours | -1.2 ± 7.06 |
| CFB at 8 Hours | 2.6 ± 11.09 |
| CFB at 10 Hours | 3.5 ± 8.53 |
| CFB at 12 Hours | -1.5 ± 6.26 |
| CFB at 14 Hours | 2.3 ± 10.02 |
| CFB at 24 Hours | 4.6 ± 11.17 |
Vital signs included supine systolic blood pressure, supine diastolic blood pressure, supine heart rate, standing systolic blood pressure, standing diastolic blood pressure, standing heart rate, temperature, and respiratory rate. CFB in temperature is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| degree Celsius | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 36.62 ± 0.14 | 36.58 ± 0.16 |
| CFB at 4 Hours | -0.03 ± 0.22 | 0.05 ± 0.25 |
| CFB at 8 Hours | -0.04 ± 0.16 | 0.06 ± 0.28 |
| CFB at 12 Hours | -0.02 ± 0.20 | 0.04 ± 0.23 |
| CFB at 12-hour Follow-up | -0.01 ± 0.22 | -0.00 ± 0.23 |
Vital signs included supine systolic blood pressure, supine diastolic blood pressure, supine heart rate, standing systolic blood pressure, standing diastolic blood pressure, standing heart rate, temperature, and respiratory rate. CFB in temperature is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| degree Celsius | Stage 2: SAGE-547 |
|---|---|
| Pre-infusion | 36.64 ± 0.15 |
| CFB at 2 Hours | -0.01 ± 0.25 |
| CFB at 4 Hours | -0.06 ± 0.20 |
| CFB at 6 Hours | 0.01 ± 0.18 |
| CFB at 8 Hours | -0.02 ± 0.23 |
| CFB at 10 Hours | 0.02 ± 0.20 |
| CFB at 12 Hours | -0.01 ± 0.40 |
| CFB at 14 Hours | 0.02 ± 0.21 |
| CFB at 24 Hours | -0.01 ± 0.29 |
Vital signs included supine systolic blood pressure, supine diastolic blood pressure, supine heart rate, standing systolic blood pressure, standing diastolic blood pressure, standing heart rate, temperature, and respiratory rate. CFB in respiratory rate is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| breaths per minute (breaths/min) | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 16.0 ± 1.53 | 16.3 ± 1.46 |
| CFB at 4 Hours | 0.4 ± 2.55 | -0.2 ± 1.52 |
| CFB at 8 Hours | 0.7 ± 2.43 | 0.3 ± 2.30 |
| CFB at 12 Hours | 1.0 ± 2.30 | 0.4 ± 2.04 |
| CFB at 12-hour Follow-up | 0.4 ± 1.70 | 0.2 ± 1.31 |
Vital signs included supine systolic blood pressure, supine diastolic blood pressure, supine heart rate, standing systolic blood pressure, standing diastolic blood pressure, standing heart rate, temperature, and respiratory rate. CFB in respiratory rate is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| breaths/min | Stage 2: SAGE-547 |
|---|---|
| Pre-infusion | 16.9 ± 1.75 |
| CFB at 2 Hours | -0.5 ± 1.81 |
| CFB at 4 Hours | -0.4 ± 2.22 |
| CFB at 6 Hours | -0.9 ± 2.31 |
| CFB at 8 Hours | -0.4 ± 1.82 |
| CFB at 10 Hours | 0.3 ± 1.24 |
| CFB at 12 Hours | 0.5 ± 2.13 |
| CFB at 14 Hours | 0.1 ± 2.33 |
| CFB at 24 Hours | -0.5 ± 2.00 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in alanine aminotransferase levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| units per liter (u/L) | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 22.0 ± 12.15 | 23.3 ± 14.67 |
| CFB at 12-hour Follow-up | -1.4 ± 4.05 | -2.7 ± 5.69 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for alanine aminotransferase levels are reported in this outcome measure.
| u/L | Stage 2: SAGE-547 |
|---|---|
| Any Day in Screening Period (Day -7 up to Day -1) | 23.1 ± 11.81 |
| Any Day in 7-day Follow-up | 23.6 ± 13.06 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in aspartate aminotransferase levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| u/L | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 19.2 ± 6.31 | 19.0 ± 5.81 |
| CFB at 12-hour Follow-up | -0.7 ± 3.92 | -0.0 ± 4.32 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for aspartate aminotransferase levels are reported in this outcome measure.
| u/L | Stage 2: SAGE-547 |
|---|---|
| Any Day in Screening Period (Day -7 up to Day -1) | 15.8 ± 4.82 |
| Any Day in 7-day Follow-up | 15.6 ± 5.66 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in gamma glutamyl transferase levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| u/L | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 27.0 ± 24.32 | 25.2 ± 21.40 |
| CFB at 12-hour Follow-up | 0.0 ± 4.16 | 1.2 ± 2.94 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for gamma glutamyl transferase levels are reported in this outcome measure.
| u/L | Stage 2: SAGE-547 |
|---|---|
| Any Day in Screening Period (Day -7 up to Day -1) | 26.8 ± 21.72 |
| Any Day in 7-day Follow-up | 28.3 ± 19.65 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in sodium levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| millimoles per liter (mmol/L) | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 140.4 ± 2.38 | 140.2 ± 2.35 |
| CFB at 12-hour Follow-up | -0.2 ± 2.19 | -0.6 ± 3.28 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for sodium levels are reported in this outcome measure.
| mmol/L | Stage 2: SAGE-547 |
|---|---|
| Any Day in Screening Period (Day -7 up to Day -1) | 139.4 ± 2.18 |
| Any Day in 7-day Follow-up | 139.4 ± 1.91 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in potassium levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| mmol/L | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 4.18 ± 0.273 | 4.17 ± 0.301 |
| CFB at 12-hour Follow-up | -0.00 ± 0.301 | 0.10 ± 0.335 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for potassium levels are reported in this outcome measure.
| mmol/L | Stage 2: SAGE-547 |
|---|---|
| Any Day in Screening Period (Day -7 up to Day -1) | 4.36 ± 0.232 |
| Any Day in 7-day Follow-up | 4.42 ± 0.268 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in calcium levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| milligrams per deciliter (mg/dL) | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 9.07 ± 0.366 | 9.08 ± 0.376 |
| CFB at 12-hour Follow-up | -0.11 ± 0.492 | -0.12 ± 0.393 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for calcium levels are reported in this outcome measure.
| mg/dL | Stage 2: SAGE-547 |
|---|---|
| Any Day in Screening Period (Day -7 up to Day -1) | 9.19 ± 0.302 |
| Any Day in 7-day Follow-up | 9.12 ± 0.268 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in chloride levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| mmol/L | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 106.4 ± 3.34 | 105.8 ± 3.00 |
| CFB at 12-hour Follow-up | -0.2 ± 2.54 | -0.2 ± 2.00 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for chloride levels are reported in this outcome measure.
| mmol/L | Stage 2: SAGE-547 |
|---|---|
| Any Day in Screening Period (Day -7 up to Day -1) | 103.8 ± 2.79 |
| Any Day in 7-day Follow-up | 104.2 ± 2.54 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in bicarbonate levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| mmol/L | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 25.6 ± 3.47 | 25.6 ± 2.87 |
| CFB at 12-hour Follow-up | -0.4 ± 2.71 | -0.7 ± 2.95 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for bicarbonate levels are reported in this outcome measure.
| mmol/L | Stage 2: SAGE-547 |
|---|---|
| Any Day in Screening Period (Day -7 up to Day -1) | 26.6 ± 3.91 |
| Any Day in 7-day Follow-up | 26.3 ± 3.60 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in protein levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| grams per deciliter (g/dL) | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 6.70 ± 0.452 | 6.66 ± 0.390 |
| CFB at 12-hour Follow-up | -0.08 ± 0.456 | 0.05 ± 0.366 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for protein levels are reported in this outcome measure.
| g/dL | Stage 2: SAGE-547 |
|---|---|
| Any Day in Screening Period (Day -7 up to Day -1) | 7.05 ± 0.403 |
| Any Day in 7-day Follow-up | 6.80 ± 0.417 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in glucose levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| mg/dL | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 108.0 ± 34.29 | 95.4 ± 17.21 |
| CFB at 12-hour Follow-up | 0.0 ± 38.89 | 19.6 ± 52.94 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for glucose levels are reported in this outcome measure.
| mg/dL | Stage 2: SAGE-547 |
|---|---|
| Any Day in Screening Period (Day -7 up to Day -1) | 108.1 ± 60.88 |
| Any Day in 7-day Follow-up | 112.8 ± 71.74 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in lactate dehydrogenase levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| u/L | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 167.9 ± 32.75 | 153.1 ± 29.87 |
| CFB at 12-hour Follow-up | -16.6 ± 15.59 | -0.8 ± 17.57 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for lactate dehydrogenase levels are reported in this outcome measure.
| u/L | Stage 2: SAGE-547 |
|---|---|
| Any Day in Screening Period (Day -7 up to Day -1) | 162.9 ± 39.06 |
| Any Day in 7-day Follow-up | 168.8 ± 40.97 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in cholesterol levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| mg/dL | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 183.0 ± 32.77 | 183.4 ± 24.63 |
| CFB at 12-hour Follow-up | 0.4 ± 14.01 | 2.1 ± 20.84 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for cholesterol levels are reported in this outcome measure.
| mg/dL | Stage 2: SAGE-547 |
|---|---|
| Any Day in Screening Period (Day -7 up to Day -1) | 194.6 ± 39.64 |
| Any Day in 7-day Follow-up | 179.7 ± 33.94 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in triglyceride levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| mg/dL | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 166.1 ± 93.42 | 168.4 ± 77.72 |
| CFB at 12-hour Follow-up | -19.1 ± 67.47 | -25.1 ± 45.41 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for triglyceride levels are reported in this outcome measure.
| mg/dL | Stage 2: SAGE-547 |
|---|---|
| Any Day in Screening Period (Day -7 up to Day -1) | 162.4 ± 63.59 |
| Any Day in 7-day Follow-up | 163.4 ± 69.94 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in albumin levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| g/dL | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 3.94 ± 0.260 | 3.95 ± 0.315 |
| CFB at 12-hour Follow-up | -0.06 ± 0.314 | -0.01 ± 0.276 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for albumin levels are reported in this outcome measure.
| g/dL | Stage 2: SAGE-547 |
|---|---|
| Any Day in Screening Period (Day -7 up to Day -1) | 4.03 ± 0.331 |
| Any Day in 7-day Follow-up | 3.92 ± 0.299 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in bilirubin levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| mg/dL | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 0.44 ± 0.231 | 0.47 ± 0.313 |
| CFB at 12-hour Follow-up | 0.04 ± 0.144 | 0.09 ± 0.127 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for bilirubin levels are reported in this outcome measure.
| mg/dL | Stage 2: SAGE-547 |
|---|---|
| Any Day in Screening Period (Day -7 up to Day -1) | 0.58 ± 0.354 |
| Any Day in 7-day Follow-up | 0.57 ± 0.463 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in creatinine levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| mg/dL | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 0.940 ± 0.2480 | 0.951 ± 0.2912 |
| CFB at 12-hour Follow-up | -0.07 ± 0.104 | -0.09 ± 0.128 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for creatinine levels are reported in this outcome measure.
| mg/dL | Stage 2: SAGE-547 |
|---|---|
| Any Day in Screening Period (Day -7 up to Day -1) | 0.872 ± 0.2302 |
| Any Day in 7-day Follow-up | 0.912 ± 0.2234 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in blood urea nitrogen levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| mg/dL | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 18.1 ± 4.60 | 17.9 ± 5.73 |
| CFB at 12-hour Follow-up | -0.4 ± 4.36 | -0.3 ± 3.08 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for blood urea nitrogen levels are reported in this outcome measure.
| mg/dL | Stage 2: SAGE-547 |
|---|---|
| Any Day in Screening Period (Day -7 up to Day -1) | 17.3 ± 4.31 |
| Any Day in 7-day Follow-up | 16.6 ± 3.37 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in alkaline phosphatase levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| u/L | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 69.1 ± 13.97 | 67.1 ± 13.58 |
| CFB at 12-hour Follow-up | -2.4 ± 5.37 | -0.4 ± 6.83 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for alkaline phosphatase levels are reported in this outcome measure.
| u/L | Stage 2: SAGE-547 |
|---|---|
| Any Day in Screening Period (Day -7 up to Day -1) | 71.1 ± 13.99 |
| Any Day in 7-day Follow-up | 71.4 ± 14.33 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in creatinine kinase levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| u/L | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 100.5 ± 71.25 | 124.0 ± 188.98 |
| CFB at 12-hour Follow-up | -20.6 ± 25.57 | -36.2 ± 90.71 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for creatinine kinase levels are reported in this outcome measure.
| u/L | Stage 2: SAGE-547 |
|---|---|
| Any Day in Screening Period (Day -7 up to Day -1) | 83.9 ± 32.51 |
| Any Day in 7-day Follow-up | 85.9 ± 44.45 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in phosphate levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| mg/dL | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 3.58 ± 0.468 | 3.52 ± 0.551 |
| CFB at 12-hour Follow-up | -0.16 ± 0.481 | -0.17 ± 0.581 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for phosphate levels are reported in this outcome measure.
| mg/dL | Stage 2: SAGE-547 |
|---|---|
| Any Day in Screening Period (Day -7 up to Day -1) | 3.36 ± 0.436 |
| Any Day in 7-day Follow-up | 3.23 ± 0.461 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. CFB in urate levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| mg/dL | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 4.53 ± 1.249 | 4.71 ± 1.366 |
| CFB at 12-hour Follow-up | 0.05 ± 0.532 | -0.04 ± 0.317 |
Serum chemistry parameters included alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, sodium, potassium, calcium, chloride, bicarbonate, protein, glucose, lactate dehydrogenase, cholesterol, triglycerides, albumin, bilirubin, creatinine, blood urea nitrogen, alkaline phosphatase, creatinine kinase, phosphate, and urate. Absolute values for urate levels are reported in this outcome measure.
| mg/dL | Stage 2: SAGE-547 |
|---|---|
| Any Day in Screening Period (Day -7 up to Day -1) | 4.66 ± 1.169 |
| Any Day in 7-day Follow-up | 4.84 ± 1.183 |
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. CFB in hemoglobin levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| g/dL | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 13.56 ± 1.276 | 13.63 ± 1.179 |
| CFB at 12-hours Follow-up | 0.34 ± 0.733 | 0.28 ± 0.768 |
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. Absolute values for hemoglobin levels are reported in this outcome measure.
| g/dL | Stage 2: SAGE-547 |
|---|---|
| Any Day in Screening Period (Day -7 up to Day -1) | 14.74 ± 1.419 |
| Any Day in 7-day Follow-up | 14.11 ± 1.684 |
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. CFB in hematocrit levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| percentage of cells | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 40.66 ± 3.463 | 40.97 ± 3.453 |
| CFB at 12-hours Follow-up | 1.02 ± 2.013 | 0.67 ± 2.494 |
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. Absolute values for hematocrit levels are reported in this outcome measure.
| percentage of cells | Stage 2: SAGE-547 |
|---|---|
| Any Day in Screening Period (Day -7 up to Day -1) | 45.04 ± 4.230 |
| Any Day in 7-day Follow-up | 43.28 ± 5.128 |
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. CFB in platelet levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| 10^3 cells per microliter(10^3 cells/μL) | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 212.5 ± 40.56 | 218.8 ± 48.31 |
| CFB at 12-hours Follow-up | -11.7 ± 45.02 | -7.1 ± 37.11 |
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. Absolute values for platelet levels are reported in this outcome measure.
| 10^3 cells/μL | Stage 2: SAGE-547 |
|---|---|
| Any Day in Screening Period (Day -7 up to Day -1) | 233.8 ± 48.03 |
| Any Day in 7-day Follow-up | 230.5 ± 45.93 |
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. CFB in erythrocyte levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| 10^6 cells per microliter(10^6 cells/μL) | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 4.437 ± 0.4032 | 4.474 ± 0.4119 |
| CFB at 12-hours Follow-up | 0.09 ± 0.223 | 0.07 ± 0.271 |
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. Absolute values for erythrocyte levels are reported in this outcome measure.
| 10^6 cells/μL | Stage 2: SAGE-547 |
|---|---|
| Any Day in Screening Period (Day -7 up to Day -1) | 4.925 ± 0.4173 |
| Any Day in 7-day Follow-up | 4.735 ± 0.5289 |
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. CFB in neutrophil levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| 10^3 cells/μL | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 4.510 ± 1.2311 | 4.781 ± 1.6007 |
| CFB at 12-hours Follow-up | -0.49 ± 0.941 | -0.66 ± 1.053 |
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. Absolute values for neutrophil levels are reported in this outcome measure.
| 10^3 cells/μL | Stage 2: SAGE-547 |
|---|---|
| Any Day in Screening Period (Day -7 up to Day -1) | 4.049 ± 0.8958 |
| Any Day in 7-day Follow-up | 4.176 ± 0.8065 |
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. CFB in basophil levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| cells per microliter (cells/μL) | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 25.4 ± 15.61 | 27.2 ± 20.45 |
| CFB at 12-hours Follow-up | 6.4 ± 17.06 | -8.3 ± 21.83 |
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. Absolute values for basophil levels are reported in this outcome measure.
| cells/μL | Stage 2: SAGE-547 |
|---|---|
| Any Day in Screening Period (Day -7 up to Day -1) | 35.3 ± 20.70 |
| Any Day in 7-day Follow-up | 45.3 ± 47.64 |
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. CFB in eosinophil levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| cells/μL | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 158.8 ± 77.53 | 140.3 ± 109.72 |
| CFB at 12-hours Follow-up | 11.5 ± 45.21 | 42.5 ± 47.48 |
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. Absolute values for eosinophil levels are reported in this outcome measure.
| cells/μL | Stage 2: SAGE-547 |
|---|---|
| Any Day in Screening Period (Day -7 up to Day -1) | 87.2 ± 40.49 |
| Any Day in 7-day Follow-up | 99.8 ± 75.37 |
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. CFB in monocyte levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| cells/μL | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 480.5 ± 264.68 | 462.8 ± 240.92 |
| CFB at 12-hours Follow-up | -22.9 ± 176.01 | -40.3 ± 113.21 |
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. Absolute values for monocyte levels are reported in this outcome measure.
| cells/μL | Stage 2: SAGE-547 |
|---|---|
| Any Day in Screening Period (Day -7 up to Day -1) | 499.8 ± 190.38 |
| Any Day in 7-day Follow-up | 426.7 ± 133.11 |
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. CFB in lymphocyte levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| cells/μL | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 1641.7 ± 423.63 | 1590.1 ± 427.61 |
| CFB at 12-hours Follow-up | 176.5 ± 244.63 | 100.3 ± 310.99 |
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. Absolute values for lymphocyte levels are reported in this outcome measure.
| cells/μL | Stage 2: SAGE-547 |
|---|---|
| Any Day in Screening Period (Day -7 up to Day -1) | 2080.0 ± 908.52 |
| Any Day in 7-day Follow-up | 1871.8 ± 858.64 |
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. CFB in leukocyte levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| 10^3 cells/μL | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 6.976 ± 1.9550 | 6.972 ± 2.1314 |
| CFB at 12-hours Follow-up | -0.12 ± 1.090 | -0.43 ± 0.927 |
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. Absolute values for leukocyte levels are reported in this outcome measure.
| 10^3 cells/μL | Stage 2: SAGE-547 |
|---|---|
| Any Day in Screening Period (Day -7 up to Day -1) | 6.928 ± 1.7603 |
| Any Day in 7-day Follow-up | 6.688 ± 1.5791 |
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. CFB in erythrocytes mean corpuscular volume levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| femtoliter (fL) | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 91.71 ± 3.774 | 91.72 ± 3.780 |
| CFB at 12-hours Follow-up | 0.30 ± 0.810 | -0.03 ± 0.833 |
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. Absolute values for erythrocytes mean corpuscular volume levels are reported in this outcome measure.
| fL | Stage 2: SAGE-547 |
|---|---|
| Any Day in Screening Period (Day -7 up to Day -1) | 91.59 ± 5.264 |
| Any Day in 7-day Follow-up | 91.43 ± 4.718 |
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. CFB in mean cell hemoglobin levels is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| picograms (pg) | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 30.58 ± 1.540 | 30.90 ± 1.760 |
| CFB at 12-hours Follow-up | 0.18 ± 0.468 | -0.30 ± 0.792 |
Hematology parameters included hemoglobin, hematocrit, platelets, erythrocytes, neutrophils, basophils, eosinophils, monocytes, lymphocytes, leukocytes, erythrocytes mean corpuscular volume, and mean cell hemoglobin. Absolute values for mean cell hemoglobin levels are reported in this outcome measure.
| pg | Stage 2: SAGE-547 |
|---|---|
| Any Day in Screening Period (Day -7 up to Day -1) | 29.93 ± 2.890 |
| Any Day in 7-day Follow-up | 29.97 ± 2.809 |
ECG parameters included QT interval, PR interval, QRS duration, QTcB interval, QTcF interval, and heart rate. CFB in QT interval is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| milliseconds (msec) | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 392.0 (362 to 493) | 394.0 (359 to 462) |
| CFB at 4 Hours | 3.0 (-88 to 28) | -2.0 (-31 to 26) |
| CFB at 8 Hours | -8.0 (-92 to 18) | -10.0 (-64 to 38) |
| CFB at 12 Hours | -12.0 (-90 to 24) | -14.0 (-48 to 32) |
ECG parameters included QT interval, PR interval, QRS duration, QTcB interval, QTcF interval, and heart rate. CFB in QT interval is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| msec | Stage 2: SAGE-547 |
|---|---|
| Pre-infusion | 376.0 (368 to 422) |
| CFB at 10 Hours | -1.0 (-33 to 28) |
ECG parameters included QT interval, PR interval, QRS duration, QTcB interval, QTcF interval, and heart rate. CFB in PR interval is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| msec | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 168.0 (108 to 214) | 170.0 (116 to 262) |
| CFB at 4 Hours | 0.0 (-168 to 46) | -4.0 (-46 to 28) |
| CFB at 8 Hours | -3.0 (-18 to 54) | -2.0 (-30 to 18) |
| CFB at 12 Hours | -4.0 (-158 to 74) | -6.0 (-52 to 39) |
ECG parameters included QT interval, PR interval, QRS duration, QTcB interval, QTcF interval, and heart rate. CFB in PR interval is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| msec | Stage 2: SAGE-547 |
|---|---|
| Pre-infusion | 144.0 (136 to 174) |
| CFB at 10 Hours | 2.5 (-6 to 43) |
ECG parameters included QT interval, PR interval, QRS duration, QTcB interval, QTcF interval, and heart rate. CFB in QRS duration is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| msec | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 86.0 (72 to 236) | 85.0 (72 to 122) |
| CFB at 4 Hours | 0.0 (-162 to 15) | 0.0 (-10 to 6) |
| CFB at 8 Hours | 0.0 (-166 to 9) | 0.0 (-8 to 13) |
| CFB at 12 Hours | 0.0 (-162 to 22) | 0.0 (-13 to 15) |
ECG parameters included QT interval, PR interval, QRS duration, QTcB interval, QTcF interval, and heart rate. CFB in QRS duration is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| msec | Stage 2: SAGE-547 |
|---|---|
| Pre-infusion | 90.0 (74 to 122) |
| CFB at 10 Hours | 0.0 (-6 to 15) |
ECG parameters included QT interval, PR interval, QRS duration, QTcB interval, QTcF interval, and heart rate. CFB in QTcB interval is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| msec | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 412.0 (380 to 524) | 413.0 (383 to 455) |
| CFB at 4 Hours | -1.0 (-111 to 18) | 1.0 (-27 to 20) |
| CFB at 8 Hours | 5.0 (-115 to 28) | 0.0 (-25 to 20) |
| CFB at 12 Hours | 4.0 (-108 to 78) | -1.0 (-18 to 24) |
ECG parameters included QT interval, PR interval, QRS duration, QTcB interval, QTcF interval, and heart rate. CFB in QTcB interval is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| msec | Stage 2: SAGE-547 |
|---|---|
| Pre-infusion | 421.0 (391 to 446) |
| CFB at 10 Hours | 1.5 (-22 to 25) |
ECG parameters included QT interval, PR interval, QRS duration, QTcB interval, QTcF interval, and heart rate. CFB in QTcF interval is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| msec | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 404.0 (380 to 502) | 404.0 (389 to 451) |
| CFB at 4 Hours | 2.0 (-103 to 20) | 0.0 (-24 to 18) |
| CFB at 8 Hours | 1.0 (-108 to 17) | -3.0 (-17 to 20) |
| CFB at 12 Hours | 1.0 (-102 to 59) | -7.0 (-17 to 23) |
ECG parameters included QT interval, PR interval, QRS duration, QTcB interval, QTcF interval, and heart rate. CFB in QTcF interval is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| msec | Stage 2: SAGE-547 |
|---|---|
| Pre-infusion | 406.0 (386 to 438) |
| CFB at 10 Hours | 2.5 (-15 to 26) |
ECG parameters included QT interval, PR interval, QRS duration, QTcB interval, QTcF interval, and heart rate. CFB in heart rate is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| bpm | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 65.0 ± 9.70 | 65.0 ± 9.09 |
| CFB at 4 Hours | -1.9 ± 6.36 | 0.2 ± 4.33 |
| CFB at 8 Hours | 3.3 ± 6.46 | 3.0 ± 9.05 |
| CFB at 12 Hours | 5.5 ± 7.35 | 4.6 ± 7.34 |
ECG parameters included QT interval, PR interval, QRS duration, QTcB interval, QTcF interval, and heart rate. CFB in heart rate is reported in this outcome measure. Baseline is defined as the pre-infusion value in each period/stage.
| bpm | Stage 2: SAGE-547 |
|---|---|
| Pre-infusion | 72.0 ± 8.27 |
| CFB at 10 Hours | -0.4 ± 5.97 |
Accelerometer total score response was defined as ≥30% decrease from baseline to each time point in accelerometer total score. Accelerometer total score is sum of forward outstretched postural tremor, lateral wing-beating postural tremor, and kinetic tremor scores across both sides of the body (i.e., right and left). Accelerometer was used for transducer measurement of tremor amplitude. Participants wore wireless ring motion sensor. It measured linear acceleration and angular velocity (i.e., kinesia score). Information from motion sensor data was correlated to symptoms of tremor. Kinesia (accelerometer) scores ranged from 0 to 4 in 0.5 step increments. The total score ranges from 0 to 24, higher scores indicating more severe tremors. Negative change from baseline indicated decrease in tremor. Baseline is defined as the pre-infusion value in each period/stage.
| score on a scale | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 7.13 ± 3.902 | 7.41 ± 4.137 |
| CFB at 2 Hours | -0.96 ± 1.373 | -1.05 ± 1.563 |
| CFB at 4 Hours | -0.83 ± 1.876 | -0.74 ± 1.833 |
| CFB at 6 Hours | -1.25 ± 1.943 | -0.75 ± 1.186 |
| CFB at 8 Hours | -0.93 ± 1.903 | -1.03 ± 1.447 |
| CFB at 10 Hours | -1.24 ± 1.814 | -0.85 ± 1.713 |
| CFB at 12 Hours | -1.39 ± 1.436 | -0.91 ± 1.284 |
| CFB at 12-hour Follow-up | 0.05 ± 1.498 | -0.21 ± 1.927 |
Accelerometer total score response was defined as ≥30% decrease from baseline to each time point in accelerometer total score. Accelerometer total score is sum of forward outstretched postural tremor, lateral wing beating postural tremor, and kinetic tremor scores across both sides of the body (i.e., right and left). Accelerometer was used for transducer measurement of tremor amplitude. Participants wore wireless ring motion sensor. It measured linear acceleration and angular velocity (i.e., kinesia score). Information from motion sensor data was correlated to symptoms of tremor. Kinesia (accelerometer) scores ranged from 0 to 4 in 0.5 step increments. The total score ranges from 0 to 24, higher scores indicating more severe tremors. Negative change from baseline indicated decrease in tremor. Baseline is defined as the pre-infusion value in each period/stage.
| score on a scale | Stage 2: SAGE-547 |
|---|---|
| Baseline | 6.96 ± 4.901 |
| CFB at 2 Hours | -1.37 ± 2.202 |
| CFB at 3 Hours | -1.25 ± 1.890 |
| CFB at 4 Hours | -1.57 ± 2.186 |
| CFB at 6 Hours | -1.44 ± 2.553 |
| CFB at 8 Hours | -2.06 ± 2.942 |
| CFB at 10 Hours | -1.16 ± 1.809 |
| CFB at 12 Hours | -0.89 ± 1.845 |
| CFB at 14 Hours | -0.35 ± 1.780 |
| CFB at 24 Hours | 0.18 ± 2.033 |
The TETRAS PS total score was calculated as the sum of items 4 (upper-limb), 6 (Archimedes spiral), 7 (handwriting), and 8 (dot approximation). TETRAS PS upper-limb total score was calculated as the sum of the 6 separate upper-limb maneuvers assessed by the clinician: forward-outstretched postural tremor \[right\], forward outstretched postural tremor \[left\], lateral wing-beating postural tremor \[right\], lateral wing-beating postural tremor \[left\], kinetic tremor \[right\], kinetic tremor \[left\], each on a 0 (no tremor) to 4 (maximum tremor) severity scale in 0.5-point increments. TETRAS Part 4 score for both upper limbs ranged from 0 to 24, higher scores indicated more severe tremor. A negative change from baseline indicated less tremor. Baseline is defined as the pre-infusion value in each period/stage.
| score on a scale | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 9.48 ± 3.917 | 9.72 ± 3.199 |
| CFB at 2 Hours | -2.10 ± 2.309 | -2.10 ± 1.860 |
| CFB at 4 Hours | -2.06 ± 2.205 | -2.72 ± 2.107 |
| CFB at 6 Hours | -2.94 ± 2.007 | -1.84 ± 1.553 |
| CFB at 8 Hours | -2.94 ± 2.682 | -2.74 ± 1.943 |
| CFB at 10 Hours | -2.94 ± 2.505 | -2.60 ± 1.898 |
| CFB at 12 Hours | -3.48 ± 2.632 | -2.46 ± 2.031 |
| CFB at 12-hour Follow-up | -1.38 ± 1.943 | -1.70 ± 1.507 |
The TETRAS PS total score was calculated as the sum of items 4 (upper-limb), 6 (Archimedes spiral), 7 (handwriting), and 8 (dot approximation). TETRAS PS upper-limb total score was calculated as the sum of the 6 separate upper-limb maneuvers assessed by the clinician: forward-outstretched postural tremor \[right\], forward outstretched postural tremor \[left\], lateral wing-beating postural tremor \[right\], lateral wing-beating postural tremor \[left\], kinetic tremor \[right\], kinetic tremor \[left\], each on a 0 (no tremor) to 4 (maximum tremor) severity scale in 0.5-point increments. TETRAS Part 4 score for both upper limbs ranged from 0 to 24, higher scores indicated more severe tremor. A negative change from baseline indicated less tremor.
| score on a scale | Stage 2: SAGE-547 |
|---|---|
| Baseline | 9.24 ± 1.977 |
| CFB at 2 Hours | -1.66 ± 2.173 |
| CFB at 3 Hours | -2.44 ± 2.542 |
| CFB at 4 Hours | -3.25 ± 2.550 |
| CFB at 6 Hours | -2.66 ± 2.612 |
| CFB at 8 Hours | -3.16 ± 2.809 |
| CFB at 10 Hours | -2.19 ± 1.642 |
| CFB at 12 Hours | -1.25 ± 1.602 |
| CFB at 14 Hours | -0.66 ± 1.091 |
| CFB at 24 Hours | -0.84 ± 1.850 |
SSS is a participant-rated scale designed to quickly assess how alert a participant was feeling. Degrees of sleepiness and alertness were rated on a scale of 1 to 7, where the lowest score of '1' indicated the participant was 'feeling active, vital, alert, or wide awake' and the highest score of '7' indicated the participant was 'no longer fighting sleep, sleep onset soon; having dream-like thoughts'. Baseline is defined as the pre-infusion value in each period. A negative change from baseline indicated less sleepiness.
| score on a scale | Stage 1: SAGE-547 | Stage 1: Placebo |
|---|---|---|
| Pre-infusion | 1.6 ± 0.77 | 1.6 ± 0.76 |
| CFB at 2 Hours | 0.3 ± 1.37 | 0.0 ± 0.41 |
| CFB at 4 Hours | 0.3 ± 1.40 | 0.1 ± 0.53 |
| CFB at 6 Hours | 0.7 ± 1.09 | 0.1 ± 0.83 |
| CFB at 8 Hours | 0.1 ± 1.08 | 0.0 ± 0.82 |
| CFB at 10 Hours | 0.3 ± 1.40 | 0.2 ± 0.93 |
| CFB at 12 Hours | 0.2 ± 0.87 | -0.0 ± 0.89 |
| CFB at 12-hour Follow-up | -0.1 ± 0.54 | -0.2 ± 0.75 |
SSS is a participant-rated scale designed to quickly assess how alert a participant was feeling. Degrees of sleepiness and alertness were rated on a scale of 1 to 7, where the lowest score of '1' indicated the participant was 'feeling active, vital, alert, or wide awake' and the highest score of '7' indicated the participant was 'no longer fighting sleep, sleep onset soon; having dream-like thoughts'. Baseline is defined as the pre-infusion value in each period. A negative change from baseline indicated less sleepiness.
| score on a scale | Stage 2: SAGE-547 |
|---|---|
| Baseline | 1.5 ± 0.62 |
| CFB at 1 Hour | 0.4 ± 1.12 |
| CFB at 2 Hours | 1.4 ± 1.09 |
| CFB at 3 Hours | 2.5 ± 2.10 |
| CFB at 4 Hours | 3.1 ± 1.81 |
| CFB at 5 Hours | 3.3 ± 2.02 |
| CFB at 6 Hours | 3.3 ± 1.91 |
| CFB at 7 Hours | 2.6 ± 1.79 |
| CFB at 8 Hours | 2.4 ± 1.86 |
| CFB at 9 Hours | 2.3 ± 1.91 |
| CFB at 10 Hours | 2.0 ± 1.97 |
| CFB at 11 Hours | 0.1 ± 0.85 |
| CFB at 12 Hours | -0.3 ± 0.86 |
| CFB at 14 Hours | 0.3 ± 1.44 |
| CFB at 24 Hours | -0.3 ± 0.86 |
| nanograms per milliliter (ng/mL) | Stage 1: SAGE-547 |
|---|---|
| Stage 1: Maximum Peak Plasma Concentration (Cmax) of SAGE-547 | 84.3 ± 28.2 |
| ng/mL | Stage 2: SAGE-547 |
|---|---|
| Stage 2: Maximum Peak Plasma Concentration (Cmax) of SAGE-547 | 152 ± 36 |
| hours | Stage 1: SAGE-547 |
|---|---|
| Stage 1: Time to Maximum Peak Plasma Concentration (Cmax) of SAGE-547 | 10 (1 to 12.483) |
| hours | Stage 2: SAGE-547 |
|---|---|
| Stage 2: Time to Maximum Peak Plasma Concentration (Cmax) of SAGE-547 | 6 (2.967 to 9.05) |
| nanograms*hours per milliliter (ng*h/mL) | Stage 1: SAGE-547 |
|---|---|
| Stage 1: Area Under the Plasma Concentration Time Curve up to the Time of the Last Quantifiable Sample (AUClast) of SAGE-547 | 654 ± 251 |
| ng*h/mL | Stage 2: SAGE-547 |
|---|---|
| Stage 2: Area Under the Plasma Concentration Time Curve up to the Time of the Last Quantifiable Sample (AUClast) of SAGE-547 | 1310 ± 300 |
| ng*h/mL | Stage 1: SAGE-547 |
|---|---|
| Stage 1: Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of SAGE-547 | 716 ± 286 |
| ng*h/mL | Stage 2: SAGE-547 |
|---|---|
| Stage 2: Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of SAGE-547 | 1380 ± 300 |
Clearance is defined as the volume of plasma from which a substance is completely removed per unit time.
| liters per hour per kilogram (L/h/kg) | Stage 1: SAGE-547 |
|---|---|
| Stage 1: Clearance (CL) of SAGE-547 | 1.09 ± 0.41 |
Clearance is defined as the volume of plasma from which a substance is completely removed per unit time.
| L/h/kg | Stage 2: SAGE-547 |
|---|---|
| Stage 2: Clearance (CL) of SAGE-547 | 1.07 ± 0.28 |
Terminal half-life is defined as the time required to divide the plasma concentration by two after reaching pseudo-equilibrium.
| hours | Stage 1: SAGE-547 |
|---|---|
| Stage 1: Terminal Half-Life (t½) of SAGE-547 | 5.6 (1.8 to 12.8) |
Terminal half-life is defined as the time required to divide the plasma concentration by two after reaching pseudo-equilibrium.
| hours | Stage 2: SAGE-547 |
|---|---|
| Stage 2: Terminal Half-Life (t½) of SAGE-547 | 7.6 (4.8 to 9.5) |
Collected over Stage 1: Up to 30 days after last infusion (up to Day 40); Stage 2: Up to 30 days after last infusion (up to Day 31). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Stage 1: SAGE-547 | 0/25 (0%) | 0/25 (0%) | 1/25 (4%) |
| Stage 1: Placebo | 0/25 (0%) | 0/25 (0%) | 3/25 (12%) |
| Stage 2: SAGE-547 | 0/17 (0%) | 0/17 (0%) | 8/17 (47.1%) |
| Event | Stage 1: SAGE-547 | Stage 1: Placebo | Stage 2: SAGE-547 |
|---|---|---|---|
| FatigueGeneral disorders | 1/25 | 0/25 | 4/17 |
| DizzinessNervous system disorders | 0/25 | 2/25 | 3/17 |
| HyperbilirubinaemiaHepatobiliary disorders | 0/25 | 0/25 | 1/17 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 0/25 | 0/25 | 1/17 |
| HeadacheNervous system disorders | 0/25 | 1/25 | 1/17 |
| SedationNervous system disorders | 0/25 | 0/25 | 1/17 |
| HypotensionVascular disorders | 0/25 | 0/25 | 1/17 |
Safety population included all participants admitted into the inpatient unit who met all eligibility criteria, signed an informed consent, and who began infusion with SAGE-547 or placebo in Treatment Period 1 of Stage 1.
| Age, Continuous(years) | Stage 1 (Double-blind): SAGE-547 and Placebo |
|---|---|
| Mean | 64.2 ± 5.7 |
| Sex: Female, Male(Participants) | Stage 1 (Double-blind): SAGE-547 and Placebo |
|---|---|
| Female | 15 |
| Male | 10 |
| Ethnicity (NIH/OMB)(Participants) | Stage 1 (Double-blind): SAGE-547 and Placebo |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 24 |
| Unknown or Not Reported | 0 |
| Race/Ethnicity, Customized(Participants) | Stage 1 (Double-blind): SAGE-547 and Placebo |
|---|---|
| Black or African American | 1 |
| White | 22 |
| Other | 2 |
Plan to share: No — Data sharing will be consistent with the results submission policy of ClinicalTrials.gov.
Ran from Sep 2014 to primary completion in Aug 2015, 10 months.
Results were first posted in Jun 2022, 6 years 10 months after primary completion. A results delay was requested in Apr 2017.
Of 20 phase 2 interventional studies under Essential Tremor, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 29. This study's 10 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexanolone